CD274 and neoplasm: Combining Avadomide with PD-1/PD-L1 blockade has effectively reinvigorated exhausted T cells and improved their tumor-killing capacity.335 CC-122 has undergone extensive trials, initially establishing a maximum tolerated dose of 3.0 mg daily.